Emertec et al. invest €1.3m in Eviagenics

Emertec invested through its Emertec IV fund, a €60m FCPR vehicle raised in 2008. CapDecisif Management contributed through the SCR Génopole Premier Jour. Both backers were joined by CEA Investissement, the investment arm of French nuclear energy research organism CEA.

The fresh funds will allow Eviagenics to bring its platform to the market, but also use it to develop its own products - such as biopolymers, alcohols or polyphenols targeting the chemicals and healthcare sectors.

Paris-based Eviagenics is a biotechnology company founded in 2004. It is developing a technology platform for the efficient recombination and expression of metabolic pathways in cells. These reprogrammed cells will be able to transform sugars from cheap renewable sources like feedstock into new, high-value compounds.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Early-stage
• Healthcare
• France